WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206473

CAS#: 878385-84-3

Description: AZD-5069 is a potent and selective CXCR2 antagonist with the potential to inhibit neutrophil migration into the airways in patients with COPD. AZD-5069 was shown to inhibit binding of radiolabeled CXCL8 to human CXCR2 with a pIC50 value of 9.1. Furthermore, AZD5069 inhibited neutrophil chemotaxis, with a pA2 of approximately 9.6, and adhesion molecule expression, with a pA2 of 6.9, in response to CXCL1. AZD5069 was a slowly reversible antagonist of CXCR2 with effects of time and temperature evident on the pharmacology and binding kinetics. AZD-5069 is also potential useful for patient in inflammatory conditions.

Price and Availability


USD 150
USD 850

USD 250
USD 1250

USD 450
USD 3850

AZD-5069, purity > 98%, is in stock. The same day shipping out after order is received. Note: the estimated shipping out time for order > 1g may be 2 months.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 206473
Name: AZD-5069
CAS#: 878385-84-3
Chemical Formula: C18H22F2N4O5S2
Exact Mass: 476.09997
Molecular Weight: 476.51
Elemental Analysis: C, 45.37; H, 4.65; F, 7.97; N, 11.76; O, 16.79; S, 13.46

Synonym: AZD-5069; AZD 5069; AZD5069.

IUPAC/Chemical Name: N-(2-((2,3-difluorobenzyl)thio)-6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)pyrimidin-4-yl)azetidine-1-sulfonamide


InChi Code: InChI=1S/C18H22F2N4O5S2/c1-11(14(26)9-25)29-16-8-15(23-31(27,28)24-6-3-7-24)21-18(22-16)30-10-12-4-2-5-13(19)17(12)20/h2,4-5,8,11,14,25-26H,3,6-7,9-10H2,1H3,(H,21,22,23)/t11-,14+/m1/s1

SMILES Code: O=S(N1CCC1)(NC2=NC(SCC3=CC=CC(F)=C3F)=NC(O[C@H](C)[C@@H](O)CO)=C2)=O

Technical Data

White to off-white solid powder

>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: De Soyza A, Pavord I, Elborn JS, Smith D, Wray H, Puu M, Larsson B, Stockley
R. A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in
bronchiectasis. Eur Respir J. 2015 Sep 4. pii: ERJ-00148-2015. doi:
10.1183/13993003.00148-2015. [Epub ahead of print] PubMed PMID: 26341987.

2: Jurcevic S, Humfrey C, Uddin M, Warrington S, Larsson B, Keen C. The effect of
a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate
immune functions. Br J Clin Pharmacol. 2015 Jul 15. doi: 10.1111/bcp.12724. [Epub
ahead of print] PubMed PMID: 26182832.

3: Nicholls DJ, Wiley K, Dainty I, MacIntosh F, Phillips C, Gaw A, Mårdh CK.
Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine
receptor 2 antagonist. J Pharmacol Exp Ther. 2015 May;353(2):340-50. doi:
10.1124/jpet.114.221358. Epub 2015 Mar 3. PubMed PMID: 25736418.

4: Kirsten AM, Förster K, Radeczky E, Linnhoff A, Balint B, Watz H, Wray H,
Salkeld L, Cullberg M, Larsson B. The safety and tolerability of oral AZD5069, a
selective CXCR2 antagonist, in patients with moderate-to-severe COPD. Pulm
Pharmacol Ther. 2015 Apr;31:36-41. doi: 10.1016/j.pupt.2015.02.001. Epub 2015 Feb
11. PubMed PMID: 25681277.